Place of care and costs associated with acute episodes and remission in bipolar I disorder

被引:3
|
作者
McIntyre, Roger S. [1 ]
Higa, Sara [2 ]
Doan, Quan, V [3 ]
Amari, Diana [3 ]
Oliveri, David [3 ]
Gillard, Patrick [2 ]
Harrington, Amanda [2 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] AbbVie, Irvine, CA USA
[3] Genesis Res, Hoboken, NJ USA
关键词
Bipolar I disorder; mania; depression; remission; inpatient costs; outpatient costs; claims database analysis; ECONOMIC BURDEN; UNITED-STATES; ADHERENCE; OUTCOMES;
D O I
10.1080/13696998.2022.2120264
中图分类号
F [经济];
学科分类号
02 ;
摘要
Aims To our knowledge, literature describing the place of care and associated costs during acute bipolar I disorder (BP-I) episodes is limited. We conducted a claims-based retrospective study to address this gap. Materials and methods Adults with BP-I were identified via IBM MarketScan Commercial and Medicare Supplemental databases. The acute episode index date was defined by >= 1 inpatient BP-I claim(s) or >= 1 outpatient or >= 3 outpatient BP-I claims (depending on visit type) in a 2-week (manic/mixed) or 4-week (depressive) period. Likely acute episodes were defined as 3- and 6-week periods for manic/mixed and depressive episodes, respectively; total mental health-related medical costs (health plan + patient) were collected during these intervals and stratified by setting (inpatient versus outpatient). Initial and subsequent episodes were captured; data were reported in subgroups without and with clozapine use, a proxy for disease severity. The remission index date was the earliest outpatient claim with a bipolar remission diagnosis with no acute episode or treatment. Remission costs were collected over a 3-month period. All results were analyzed descriptively. Results A total of 41,516 patients with 130,221 acute manic/mixed episodes and 47,763 patients with 149,207 acute depressive episodes met the study criteria. Over 84% of acute episodes were treated in outpatient settings. Mental health-related medical costs for manic/mixed episodes were $15,444 for inpatient and $1,577 for outpatient settings; inpatient and outpatient costs for depressive episodes were $17,376 and $2,154, respectively. Health plans covered approximately 78% of medical costs for both episode types with and without prior clozapine use. A total of 8,143 patients met remission criteria; the total 3-month outpatient costs were $1,225. Conclusions Most BP-I acute manic/mixed or depressive episodes were treated in the outpatient setting. Episodes with inpatient care were 8-10 times more costly than outpatient-only episodes. Health plans covered most medical costs, but additional patient-incurred out-of-pocket costs remained.
引用
收藏
页码:1110 / 1117
页数:8
相关论文
共 50 条
  • [11] Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder
    Lewis Warrington
    Ilise Lombardo
    Antony Loebel
    Kathleen Ice
    CNS Drugs, 2007, 21 : 835 - 849
  • [12] Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder
    Vermeulen, An
    Piotrovsky, Vladimir
    Ludwig, Elizabeth A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (02) : 183 - 206
  • [13] Population Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Patients with Acute Episodes Associated with Bipolar I Disorder
    An Vermeulen
    Vladimir Piotrovsky
    Elizabeth A. Ludwig
    Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34 : 183 - 206
  • [14] Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
    Citrome, Leslie
    Landbloom, Ronald
    Chang, Cheng-Tao
    Earley, Willie
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2955 - 2963
  • [15] Bipolar I disorder in France :: prevalence of manic episodes and hospitalisation-related costs
    de Zélicourt, M
    Dardennes, R
    Verdoux, H
    Gandhi, G
    Papatheodorou, ML
    Edgell, ET
    Khoshnood, B
    Chomette, E
    Even, C
    Fagnani, F
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2003, 29 (03): : 248 - 253
  • [16] Cariprazine for acute mood episodes in bipolar disorder
    Roza, Thiago Henrique
    Santos Lopes, Savio Luiz
    Passos, Ives Cavalcante
    BIPOLAR DISORDERS, 2020, 22 (07) : 759 - 760
  • [17] Oxcarbazepine for acute affective episodes in bipolar disorder
    Vasudev, Akshya
    Macritchie, Karine
    Vasudev, Kamini
    Watson, Stuart
    Geddes, John
    Young, Allan H.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [18] Topiramate for acute affective episodes in bipolar disorder
    Vasudev, K
    Macritchie, K
    Geddes, J
    Watson, S
    Young, A
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [19] Tiagabine for acute affective episodes in bipolar disorder
    Vasudev, Akshya
    Macritchie, Karine
    Rao, Sanjay K.
    Geddes, John
    Young, Allan H.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [20] Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
    Maloney, Ann E.
    Sikich, Linmarie
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 749 - 766